Clinical Trial Update: Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating mocetinostat plus brentuximab vedotin in relapsed or refractory Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• Mocetinostat (mocetinostat)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-05-12